ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $18,669.75 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,095 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $18,669.75. Following the sale, the insider now directly owns 21,275 shares in the company, valued at $362,738.75. This trade represents a 4.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James Kihara also recently made the following trade(s):

• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Trading Up 0.9 %

NASDAQ ACAD opened at $17.19 on Friday. The stock has a market cap of $2.87 billion, a PE ratio of 22.04 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.15 and a 12 month high of $20.68. The company’s 50-day moving average price is $18.35 and its 200-day moving average price is $17.02.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. bought a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $40,935,000. SG Americas Securities LLC grew its stake in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Norges Bank purchased a new position in ACADIA Pharmaceuticals during the 4th quarter worth $25,555,000. Renaissance Technologies LLC raised its position in ACADIA Pharmaceuticals by 204.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company’s stock valued at $22,507,000 after purchasing an additional 823,333 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in shares of ACADIA Pharmaceuticals by 160.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company’s stock worth $23,180,000 after buying an additional 778,900 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ACAD shares. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $23.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.